HR-1-108
Became Public Law No: 108-173.
What it does
This law created Medicare Part D, a voluntary outpatient prescription drug benefit program for Medicare beneficiaries, effective January 1, 2006. It established a system of private prescription drug plans (PDPs) and integrated Medicare Advantage drug plans (MA-PDs) through which beneficiaries could enroll to receive drug coverage, with premiums, deductibles, and cost-sharing set by the law and adjusted annually. It also created a transitional drug discount card program for 2004–2005, restructured Medicare+Choice into the Medicare Advantage (MA) program, and provided premium and cost-sharing subsidies for low-income beneficiaries.
Who benefits
The approximately 40+ million Medicare beneficiaries at the time of enactment, particularly seniors and people with disabilities who lacked prior drug coverage. Low-income dual-eligible beneficiaries (enrolled in both Medicare and Medicaid) who received premium and cost-sharing subsidies. Private insurance companies and pharmacy benefit managers who were authorized to operate PDPs and MA plans. Pharmaceutical manufacturers, whose negotiated prices were shielded from direct government price-setting. Employers and retirees with existing drug coverage, who received subsidies to maintain that coverage. Pharmacies, which gained a large new insured customer base. Physicians who received grants to implement electronic prescribing systems.
Who is hurt
State governments, which were required to make payments to the federal Medicare Prescription Drug Account for dual-eligible beneficiaries previously covered under Medicaid — a cost shift from states to the federal government that also imposed new administrative obligations. Beneficiaries who fell into the "coverage gap" (the so-called donut hole between $2,250 and $3,600 in drug costs), who received no coverage during that range. Medigap supplemental insurance issuers, who were prohibited from selling new Rx-inclusive Medigap policies after January 1, 2006. Taxpayers broadly, as the program added significant long-term costs to the federal budget. Beneficiaries in regions with fewer than two competing plans, who had limited or fallback-only options.
Supporters argue
Supporters argue that before this law, nearly one in three Medicare beneficiaries had no prescription drug coverage, forcing many seniors to choose between medications and basic necessities. They contend the voluntary, market-based structure — relying on private plans to negotiate prices and bear financial risk — introduced competition that held down costs and produced premiums that came in well below initial CBO projections. They further argue the law's low-income subsidies ensured the most vulnerable beneficiaries, including dual-eligibles, received meaningful financial protection, and that the program has since enrolled tens of millions of beneficiaries with high satisfaction rates.
Opponents argue
Opponents argue that the law explicitly prohibited the federal government from directly negotiating drug prices with manufacturers — a provision that critics contend left hundreds of billions of dollars in potential savings unrealized compared to programs like the VA, which negotiates prices directly. They contend the "coverage gap" created a structural hole in coverage that left beneficiaries with the highest drug costs — often the sickest — exposed to full out-of-pocket costs at precisely the point of greatest need. They further argue the cost shift to states for dual-eligible beneficiaries imposed unfunded burdens on state Medicaid programs without adequate transition support.
Constitutional context
Congress enacted this law under its Taxing and Spending Clause authority (Art. I, §8, cl. 1) to fund a new Medicare benefit, and its Commerce Clause authority (Art. I, §8, cl. 3) to regulate private insurance markets. The conditions placed on states regarding dual-eligible beneficiaries implicate the Spending Clause coercion limits identified in NFIB v. Sebelius (2012), though the state payment requirements here were structured as mandatory contributions rather than conditions on existing Medicaid funding.
Checks and balances
Congress created the program structure and benefit parameters by statute; the Secretary of HHS gained significant administrative authority to approve plans, establish regions, and oversee enrollment, while the law explicitly prohibited the Secretary from interfering in price negotiations between drug manufacturers and private plans — a deliberate congressional check on executive pricing power.
Historical precedent
Medicare Parts A and B (Social Security Amendments of 1965) established the foundational framework of federal health insurance for seniors that this law expanded; no prior federal program had created a large-scale, private-plan-delivered prescription drug benefit of this scope.